Katie Kosko

DocwireNews

Patients with lung cancer who are at a high risk for venous thromboembolism (VTE) may benefit from primary ambulatory thromboprophylaxis (PATP), updated study results showed.The researchers, who presented their findings during the European Hematology Association 2024 Congress, reviewed 11 randomized studies to determine the potential benefit of PATP with low-molecular weight heparins and direct oral anticoagulants.&ldquo;Lung cancer remains the number one cause of cancer mortality while thrombosis confers the second leading cause of death in such patients,&rdquo; the researchers said.MEDLINE and EMBASE databases were searched through December 2023 and more than 5500 patients with lung cancer were identified from 5 randomized clinical trials (RCTs) and subgroups of an additional 6 RCTs, all of which had reduction in VTE as a primary or secondary endpoint. The anticoagulants used in these clinical trials included the following: apixaban, bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, rivaroxaban, semuloparin, and tinzaparin. Duration of the anticoagulant treatment ranged from 3-6 months. All studies were randomized 1:1 except for the PROTECHT study, which was 2:1.The researchers calculated risk ratio (RR) and risk difference (RD) for the analysis using the Mantel-Haenszel method.In examining nearly a dozen studies, they discovered that by providing PATP the relative risk reduction is 47% with a number needed to treat of 25 to prevent 1 VTE in ambulatory patients with lung cancer. Moreover, the VTE incidence was 116 (4.1%) in the PATP group compared with 207 (8.1%) in the control group. There was an RR of 0.51 (P &lt; .00001) and an absolute RD in VTE of -0.04 (P &lt; .00001).In a subgroup analysis of PATP trials, there were 114 (4.2%) VTE events in the PATP group versus 215 (8.2%) in the control group. This analysis showed a RR of 0.51 (P &lt; .00001) and an absolute RD of -0.04 (P &lt; .00001).Although this study provides insight into how PATP can help patients with lung cancer from experiencing a serious and potentially life-threatening condition, the researchers emphasized the importance of selecting the appropriate patients who are high risk for VTE. In addition, they pushed for future studies to help establish the high-risk subsets of patients with lung cancer who are receiving systemic therapy and may benefit from PATP.ReferenceWin Htut T, Zin Thein K, Hlaing Oo T. Primary ambulatory thromboprophylaxis (PATP) in patients with lung cancer undergoing systemic therapy: updated analysis of randomized studies. P1661. Presented at the European Hematology Association 2024 Congress; June 13-16; Madrid, Spain.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

How PATP May Benefit Patients With Lung Cancer Who Are at Risk of VTE

Lung Cancer

Patients with lung cancer who are at high-risk for venous thromboembolism (VTE) may benefit from primary ambulatory thromboprophylaxis (PATP).

How PATP May Benefit Patients With Lung Cancer Who Are At Risk of VTE

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe